Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations

European Respiratory Journal

Volumn 47, Issue 3, 2016, Pages 783-791

  De Vries, Maaike ^a,b   Bedke, Nicole ^b   Smithers, Natalie P ^b   Loxham, Matthew ^b   Howarth, Peter H ^b,c   Nawijn, Martijn C ^a   Davies, Donna E ^b,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c University Hospital Southampton NHS Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 29; JANUS KINASE; LACTATE DEHYDROGENASE; PROTEIN KINASE PIM 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; RANTES; STAT PROTEIN; CCL5 PROTEIN, HUMAN; CYTOKINE; GAMMA INTERFERON; IFNG PROTEIN, HUMAN; PIM1 PROTEIN, HUMAN;

ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN RHINOVIRUS A16; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINOVIRUS INFECTION; RNA ISOLATION; SIGNAL TRANSDUCTION; VIRUS REPLICATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DISEASE COURSE; METABOLISM; PHYSIOLOGY; RHINOVIRUS; VIROLOGY;

ASTHMA; CELLS, CULTURED; CHEMOKINE CCL5; CYTOKINES; DISEASE PROGRESSION; EPITHELIAL CELLS; HUMANS; INTERFERON-BETA; INTERFERON-GAMMA; PROTO-ONCOGENE PROTEINS C-PIM-1; RHINOVIRUS; VIRUS REPLICATION;

EID: 84959930939     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00171-2015     Document Type: Article

References (35)

1. Jackson DJ, Sykes A, Mallia P, et al. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011; 128: 1165-1174.
2. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012; 18: 673-683.
3. Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol 2010; 125: 1178-1187.
4. Gavala ML, Bertics PJ, Gern JE. Rhinoviruses, allergic inflammation, and asthma. Immunol Rev 2011; 242: 69-90.
5. Nawijn MC, Hackett TL, Postma DS, et al. E-cadherin: gatekeeper of airway mucosa and allergic sensitization. Trends Immunol 2011; 32: 248-255.
6. Bonjardim CA, Ferreira PC, Kroon EG. Interferons: signaling, antiviral and viral evasion. Immunol Lett 2009; 122: 1-11.
7. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30: 555-564.
8. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-386.
9. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201: 937-947.
10. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-X production in asthma exacerbations. Nat Med 2006; 12: 1023-1026.
11. Cakebread JA, Xu Y, Grainge C, et al. Exogenous IFN-p has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol 2011; 127: 1148-1154.
12. Djukanovic R, Harrison T, Johnston SL, et al. The effect of inhaled IFN-p on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 2014; 190: 145-154.
13. Dalpke A, Heeg K, Bartz H, et al. Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins. Immunobiology 2008; 213: 225-235.
14. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7: 454-465.
15. Bedke N, Sammut D, Green B, et al. Transforming growth factor-p promotes rhinovirus replication in bronchial epithelial cells by suppressing the innate immune response. PLoS One 2012; 7: e44580.
16. Chen XP, Losman JA, Cowan S, et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 2002; 99: 2175-2180.
17. de Vries M, Heijink IH, Gras R, et al. Pim1 kinase protects airway epithelial cells from cigarette smoke-induced damage and airway inflammation. Am J Physiol Lung Cell Mol Physiol 2014; 307: L240-L251.
18. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011; 11: 23-34.
19. Bucchieri F, Puddicombe SM, Lordan JL, et al. Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis. Am J Respir Cell Mol Biol 2002; 27: 179-185.
20. Xiao C, Puddicombe SM, Field S, et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol 2011; 128: 549-556.
21. Pogacic V, Bullock AN, Fedorov O, et al. Structural analysis identifies imidazo[1, 2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007; 67: 6916-6924.
22. de Vries M, Smithers NP, Howarth PH, et al. Inhibition of Pim1 kinase reduces viral replication in primary bronchial epithelial cells. Eur Respir J 2015; 45: 1745-1748.
23. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-KB-mediated transcription. J Biol Chem 1999; 274: 9707-9720.
24. O'Byrne PM. Therapeutic strategies to reduce asthma exacerbations. J Allergy Clin Immunol 2011; 128: 257-263.
25. Corne JM, Marshall C, Smith S, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet 2002; 359: 831-834.
26. Swindle EJ, Davies DE. Artificial airways for the study of respiratory disease. Expert Rev Respir Med 2011; 5: 757-765.
27. Lopez-Souza N, Dolganov G, Dubin R, et al. Resistance of differentiated human airway epithelium to infection by rhinovirus. Am J Physiol Lung Cell Mol Physiol 2004; 286: L373-L381.
28. Jakiela B, Brockman-Schneider R, Amineva S, et al. Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. Am J Respir Cell Mol Biol 2008; 38: 517-523.
29. Sykes A, Macintyre J, Edwards MR, et al. Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax 2014; 69: 240-246.
30. Lopez-Souza N, Favoreto S, Wong H, et al. In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J Allergy Clin Immunol 2009; 123: 1384-1390.
31. Jakiela B, Gielicz A, Plutecka H, et al. Th2-type cytokine-induced mucus metaplasia decreases susceptibility of human bronchial epithelium to rhinovirus infection. Am J Respir Cell Mol Biol 2014; 51: 229-241.
32. Zhang JG, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 1999; 96: 2071-2076.
33. Song JH, Kraft AS. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res 2012; 72: 294-303.
34. Yan B, Yau EX, Samanta S, et al. Singapore Gastric Cancer Consortium. Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. Gastric Cancer 2012; 15: 188-197.
35. Lin YW, Beharry ZM, Hill EG, et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010; 115: 824-833.